# Oricell Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oricell-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.oricell.com
- Total disclosed funding: $277M
- Latest round: Series C (Jan 12, 2026)
- Investors on record: 17

## About

Based in Shanghai, China and founded in 2015, Oricell Therapeutics Co., Ltd., trading as Oricell Therapeutics, is a biotech company that focuses on the research and development of tumor immune cell therapy products. The company was formerly the research and development center of The Origincell Technology Group. The company has established subsidiaries in Hong Kong and the United States. In April 2026, Oricell Therapeutics raised USD 110 million in Pre-IPO funding co-led by Vivo Capital, Shunxi Fund, Qiming Venture Partners and an unspecified investor, with participation from Sovereign Wealth Funds, Shandong High-tech Investment Corporation, Ruifeng Capital, E-Town International Industrial Investment, NGS Super, Elikon Venture and other investors.
The company's main product pipeline includes autologous CAR-T immunotherapy products for the treatment of advanced hepatocellular carcinoma, relapsed refractory multiple myeloma and other novel drugs for tumor immunotherapy. The company's products are used in diseases such as liver cancer, ovarian cancer, gastric cancer and cervical cancer.
The company generates revenue from developing cell therapies leveraging CAR-T technology.
The Pre-IPO funding raised in April 2026 will primarily be used to accelerate the company's internationalization strategy, promote the global multi-center clinical development of its core pipeline, further solidify its technological barriers in the cell therapy field, accelerate the value release of its industrialization pipeline, and fully prepare for upcoming capital market milestones.

## Funding rounds

- Series C, Jan 12, 2026, $70M — NGS Super, Qiming Venture Partners, Qatar Investment Authority, E-Town International Industrial Investment, Shunxi Fund, Elikon Venture
- Series B, Feb 28, 2023, $45M — Qiming Venture Partners, Qatar Investment Authority, RTW Investments, Xiamen C&D Emerging Industry Equity Investment
- Series B, Aug 1, 2022, $120M — Qiming Venture Partners, Shanghai Jianyi Private Equity Fund Management, Quan Capital, Xiamen C&D Emerging Industry Equity Investment, Shanghai Sci-Tech Innovation Center Capital, Shanghai Boquan Equity Investment Management, Suzhou Equity Investment Fund Management
- Series A, Jan 18, 2021, $31M — Qiming Venture Partners, Shanghai Zhangjiang Science & Technology Venture Capital, Yijing Investment, Xiamen C&D Emerging Industry Equity Investment, Zhangjiang Torch Investment, Shanghai Gaosen Asset Management
- Series A, Dec 12, 2019, $11M — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- Shanghai Zhangjiang Science & Technology Venture Capital — Series A
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series A
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series A, Series B
- Zhangjiang Torch Investment (https://capitalatlas.ai/funds/zhangjiang-torch-investment) — Series A
- Shanghai Gaosen Asset Management — Series A
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series B
- Shanghai Sci-Tech Innovation Center Capital (https://capitalatlas.ai/funds/shanghai-sci-tech-innovation-center-capital) — Series B
- Shanghai Boquan Equity Investment Management — Series B
- Suzhou Equity Investment Fund Management (https://capitalatlas.ai/funds/suzhou-equity-investment-fund-management) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B, Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- NGS Super — Series C
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series C
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series C
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series C